ImmuCell Corporation
US ˙ NasdaqCM ˙ US4525253062

Introduction

This page provides a comprehensive analysis of the known insider trading history of Joseph H Crabb. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Joseph H Crabb has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:ICCC / ImmuCell Corporation Former VP and CSO 142,845
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Joseph H Crabb. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases ICCC / ImmuCell Corporation - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ICCC / ImmuCell Corporation. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ICCC / ImmuCell Corporation Insider Trades
Insider Sales ICCC / ImmuCell Corporation - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ICCC / ImmuCell Corporation. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2016-07-08 ICCC CRABB JOSEPH H 341 6.5300 341 6.5300 2,227 131 4.9000 -555 -24.94
2016-07-08 ICCC CRABB JOSEPH H 400 6.5000 400 6.5000 2,600
2016-07-08 ICCC CRABB JOSEPH H 100 6.5100 100 6.5100 651
2016-07-08 ICCC CRABB JOSEPH H 500 6.5500 500 6.5500 3,275
2016-07-08 ICCC CRABB JOSEPH H 394 6.5900 394 6.5900 2,596
2016-07-07 ICCC CRABB JOSEPH H 6 6.5900 6 6.5900 40
2016-07-07 ICCC CRABB JOSEPH H 200 6.5300 200 6.5300 1,306
2016-07-06 ICCC CRABB JOSEPH H 900 6.6000 900 6.6000 5,940
2016-07-06 ICCC CRABB JOSEPH H 300 6.5850 300 6.5850 1,976
2016-07-06 ICCC CRABB JOSEPH H 300 6.5800 300 6.5800 1,974
2016-07-06 ICCC CRABB JOSEPH H 300 6.5700 300 6.5700 1,971
2016-07-06 ICCC CRABB JOSEPH H 326 6.5701 326 6.5701 2,142
2016-07-06 ICCC CRABB JOSEPH H 300 6.5900 300 6.5900 1,977
2016-07-05 ICCC CRABB JOSEPH H 1,100 6.6000 1,100 6.6000 7,260
2016-07-05 ICCC CRABB JOSEPH H 1,300 6.5600 1,300 6.5600 8,528
2016-07-05 ICCC CRABB JOSEPH H 100 6.5601 100 6.5601 656
2016-07-01 ICCC CRABB JOSEPH H 74 7.0000 74 7.0000 518
2016-07-01 ICCC CRABB JOSEPH H 1,200 6.9000 1,200 6.9000 8,280
2016-07-01 ICCC CRABB JOSEPH H 200 6.9500 200 6.9500 1,390
2016-07-01 ICCC CRABB JOSEPH H 200 6.9000 200 6.9000 1,380
2016-07-01 ICCC CRABB JOSEPH H 500 6.9300 500 6.9300 3,465
2016-07-01 ICCC CRABB JOSEPH H 100 6.9550 100 6.9550 696
2016-07-01 ICCC CRABB JOSEPH H 100 6.7350 100 6.7350 674
2016-07-01 ICCC CRABB JOSEPH H 100 6.7400 100 6.7400 674
2016-07-01 ICCC CRABB JOSEPH H 100 6.7850 100 6.7850 678
2016-07-01 ICCC CRABB JOSEPH H 200 6.7000 200 6.7000 1,340

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ICCC / ImmuCell Corporation Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Joseph H Crabb as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2022-03-14 2022-03-09 4 ICCC IMMUCELL CORP /DE/
Common Stock, par value $0.10 per share
D - Sale to Issuer 1,000 142,845 0.70 5.84 5,840 834,215
2018-11-27 2018-11-26 4 ICCC IMMUCELL CORP /DE/
Incentive Stock Options
M - Exercise 2 1.70 3
2018-11-27 2018-11-26 4 ICCC IMMUCELL CORP /DE/
Common Stock, par value $0.10 per share
M - Exercise 47,500 141,845 50.35 1.70 80,750 241,136
2018-11-27 2018-11-26 4 ICCC IMMUCELL CORP /DE/
Common Stock, par value $0.10 per share
D - Sale to Issuer -10,766 94,345 -10.24 7.50 -80,745 707,588
2017-02-14 2017-02-10 4 ICCC IMMUCELL CORP /DE/
Incentive Stock Options
A - Award 1,000 1,000 5.84 5,840 5,840
2016-07-12 2016-07-08 4 ICCC IMMUCELL CORP /DE/
Common Stock, par value $0.10 per share
S - Sale X -200 105,111 -0.19 6.60 -1,320 693,733
2016-07-12 2016-07-08 4 ICCC IMMUCELL CORP /DE/
Common Stock, par value $0.10 per share
S - Sale -394 105,311 -0.37 6.59 -2,596 693,999
2016-07-12 2016-07-08 4 ICCC IMMUCELL CORP /DE/
Common Stock, par value $0.10 per share
S - Sale -500 105,705 -0.47 6.55 -3,275 692,368
2016-07-12 2016-07-08 4 ICCC IMMUCELL CORP /DE/
Common Stock, par value $0.10 per share
S - Sale -100 106,205 -0.09 6.51 -651 691,395
2016-07-12 2016-07-08 4 ICCC IMMUCELL CORP /DE/
Common Stock, par value $0.10 per share
S - Sale -400 106,305 -0.37 6.50 -2,600 690,982
2016-07-12 2016-07-08 4 ICCC IMMUCELL CORP /DE/
Common Stock, par value $0.10 per share
S - Sale -341 106,705 -0.32 6.53 -2,227 696,784
2016-07-07 2016-07-07 4 ICCC IMMUCELL CORP /DE/
Common Stock, par value $0.10 per share
S - Sale X -59 107,046 -0.06 6.55 -386 701,151
2016-07-07 2016-07-07 4 ICCC IMMUCELL CORP /DE/
Common Stock, par value $0.10 per share
S - Sale -200 107,105 -0.19 6.53 -1,306 699,396
2016-07-07 2016-07-07 4 ICCC IMMUCELL CORP /DE/
Common Stock, par value $0.10 per share
S - Sale -6 107,305 -0.01 6.59 -40 707,140
2016-07-07 2016-07-06 4 ICCC IMMUCELL CORP /DE/
Common Stock, par value $0.10 per share
S - Sale -300 107,311 -0.28 6.59 -1,977 707,179
2016-07-07 2016-07-06 4 ICCC IMMUCELL CORP /DE/
Common Stock, par value $0.10 per share
S - Sale -326 107,611 -0.30 6.57 -2,142 707,015
2016-07-07 2016-07-06 4 ICCC IMMUCELL CORP /DE/
Common Stock, par value $0.10 per share
S - Sale -300 107,937 -0.28 6.57 -1,971 709,146
2016-07-07 2016-07-06 4 ICCC IMMUCELL CORP /DE/
Common Stock, par value $0.10 per share
S - Sale -300 108,237 -0.28 6.58 -1,974 712,199
2016-07-07 2016-07-06 4 ICCC IMMUCELL CORP /DE/
Common Stock, par value $0.10 per share
S - Sale -300 108,537 -0.28 6.58 -1,976 714,716
2016-07-07 2016-07-06 4 ICCC IMMUCELL CORP /DE/
Common Stock, par value $0.10 per share
S - Sale -900 108,837 -0.82 6.60 -5,940 718,324
2016-07-06 2016-07-05 4 ICCC IMMUCELL CORP /DE/
Common Stock, par value $0.10 per share
S - Sale X -100 109,737 -0.09 6.62 -662 726,459
2016-07-06 2016-07-05 4 ICCC IMMUCELL CORP /DE/
Common Stock, par value $0.10 per share
S - Sale -100 109,837 -0.09 6.56 -656 720,542
2016-07-06 2016-07-05 4 ICCC IMMUCELL CORP /DE/
Common Stock, par value $0.10 per share
S - Sale -1,300 109,937 -1.17 6.56 -8,528 721,187
2016-07-06 2016-07-05 4 ICCC IMMUCELL CORP /DE/
Common Stock, par value $0.10 per share
S - Sale -1,100 111,237 -0.98 6.60 -7,260 734,164
2016-07-06 2016-07-01 4 ICCC IMMUCELL CORP /DE/
Common Stock, par value $0.10 per share
S - Sale -200 112,337 -0.18 6.70 -1,340 752,658
2016-07-06 2016-07-01 4 ICCC IMMUCELL CORP /DE/
Common Stock, par value $0.10 per share
S - Sale -100 112,537 -0.09 6.78 -678 763,564
2016-07-06 2016-07-01 4 ICCC IMMUCELL CORP /DE/
Common Stock, par value $0.10 per share
S - Sale -100 112,637 -0.09 6.74 -674 759,173
2016-07-06 2016-07-01 4 ICCC IMMUCELL CORP /DE/
Common Stock, par value $0.10 per share
S - Sale -100 112,737 -0.09 6.74 -674 759,284
2016-07-06 2016-07-01 4 ICCC IMMUCELL CORP /DE/
Common Stock, par value $0.10 per share
S - Sale -100 112,837 -0.09 6.96 -696 784,781
2016-07-06 2016-07-01 4 ICCC IMMUCELL CORP /DE/
Common Stock, par value $0.10 per share
S - Sale -500 112,937 -0.44 6.93 -3,465 782,653
2016-07-06 2016-07-01 4 ICCC IMMUCELL CORP /DE/
Common Stock, par value $.10 per share
S - Sale -200 113,437 -0.18 6.90 -1,380 782,715
2016-07-06 2016-07-01 4 ICCC IMMUCELL CORP /DE/
Common Stock, par value $0.10 per share
S - Sale -200 113,637 -0.18 6.95 -1,390 789,777
2016-07-06 2016-07-01 4 ICCC IMMUCELL CORP /DE/
Common Stock, par value $0.10 per share
S - Sale -1,200 113,837 -1.04 6.90 -8,280 785,475
2016-07-06 2016-07-01 4 ICCC IMMUCELL CORP /DE/
Common Stock, par value $0.10 per share
S - Sale -74 115,037 -0.06 7.00 -518 805,259
2013-12-16 2013-12-13 4 ICCC IMMUCELL CORP /DE/
Incentive Stock Options
M - Exercise -1,000 0 -100.00
2013-12-16 2013-12-13 4 ICCC IMMUCELL CORP /DE/
Common Stock
M - Exercise 1,000 115,111 0.88 3.10 3,100 356,844
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)